Error message

Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of includes/bootstrap.inc).
Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of includes/bootstrap.inc).
Deprecated function: Optional parameter $type declared before required parameter $nid is implicitly treated as a required parameter in include_once() (line 1442 of includes/bootstrap.inc).

T 1069/08 (Desaturase/CALGENE) of 8.9.2011

European Case Law Identifier:

ECLI:EP:BA:2011:T106908.20110908

Date of decision:

08 September 2011

Case number:

T 1069/08

Application number:

IPC class:

Language of proceedings:

EN

Distribution:

C

Download and more information:

Decision text in EN (PDF, 93Â KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in:	EN
Versions:	Unpublished

Title of application:

Methods and compositions for synthesis of long chain polyunsaturated fatty acids

Applicant name:

Calgene LLC, et al

Opponent name:

Bayer S.A.S.

Board:

3.3.08

Headnote:

-

Relevant legal provisions:

European Patent Convention Art 83
European Patent Convention Art 56
Rules of procedure of the Boards of Appeal Art 12(2)
Rules of procedure of the Boards of Appeal Art 13(1)
Rules of procedure of the Boards of Appeal Art 13(3)

Keywords:

Admissibility of appeal (yes)
Sufficiency of disclosure (yes)
Inventive step (yes)

Catchwords:

-

Cited decisions:

G 0009/91
T 0220/83
T 0019/90
T 0939/92
T 0207/94
T 0386/94
T 0111/00
T 1120/00
T 0320/01
T 1064/01
T 1120/01
T 0604/04
T 0005/06
T 0250/06
T 0087/08

Citing decisions:

T 0775/09
T 1799/09
T 2048/10
T 0433/11
T 2308/11
T 1914/12
T 1201/14
T 1508/14

Source: http://www.epo.org/law-practice/case-law-appeals/recent/t081069eu1.html

Date retrieved: 17 May 2021

23 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

X A.56 EPC Inventive step

X A.83 EPC Disclosure of the invention

Offical Journal of the EPO

X OJ EPO SE 4/2020, p73 - V. PROCEEDINGS BEFORE THE BOARDS OF APPEAL

Case Law Book: IV Divisional Applications

X CLR IV C 4.7.2 Late submissions of new arguments in opposition proceedings

Case Law Book: V Priority

X CLR V A 4.10.1 New arguments on appeal

X CLR V A 4.10.3 New arguments and lines of attack not admitted

Case Law of the Enlarged Board

X G 0009/91 (Power to examine) of 31.3.1993

General Case Law

X T 0220/83 (Grounds for appeal) of 14.1.1986

X T 0019/90 (Onco-Mouse) of 3.10.1990

X T 0939/92 (Triazoles) of 12.9.1995

X T 0207/94 (Human beta-interferon) of 8.4.1997

X T 0386/94 (Chymosin) of 11.1.1996

X T 0111/00 (Monokine/FARBER) of 14.2.2002

X T 0320/01 (Pyridones/AVENTIS) of 12.3.2004

X T 1064/01 (Sulfamic acids/SEARLE, MONSANTO) of 25.3.2004

X T 0604/04 (PF4A receptors/GENENTECH) of 16.3.2006

X T 0005/06 (Folate complex/PURDUE RESEARCH FOUNDATION) of 23.1.2009

X T 0250/06 (Opioid receptor genes/UNIVERSITY OF CALIFORNIA) of 11.10.2007

X T 0087/08 () of 11.2.2010

X T 0775/09 (ErhÃ¶hung Glykosilierung/ROCHE) of 20.3.2012

X T 0433/11 (ErkÃ¤ltungskrankheiten/PANDALIS) of 24.5.2012

X T 1914/12 () of 13.6.2018

X T 1201/14 (Transfer of right of priority) of 9.2.2017